



030-11006

LETTER REQUEST FOR RADIOISOTOPE LICENSE AMENDMENT TO ADD THE  
CINTICHEM, INC. I-125 SOURCE FOR USE WITH OSTEON/SEIMANS  
SINGLE PHOTON ABSORPTION SYSTEM.

DATE 18 June 87

REF: RADIOISOTOPE LICENSE NUMBER 53-16421-01

Dear, US Nuclear Regulatory Commission:

Please accept this letter as our formal request to amend the license number  
listed above.

We request the addition of the Cintichem, Inc. I-125 Sealed Source, Model  
Number 6525, Registration # NY222S001S for use in the OSTEON Single Photon  
Absorptiometer Unit

The total possession limit should be 1100 mCi to facilitate the exchange  
of sources. No single source will exceed 800 mCi in nominal activity.  
All sources will be shipped and used in the OSTEON Inc. source holder.

Complete instructions regarding safe use and handling of the I-125 source  
will be provided with each source by Contichem, Inc. Sources will only  
be handled by the manufacturer's instructions.

The OSTEON #SPSHA 110 Single Photon Absorption System is licensed by the  
U.S. Nuclear Regulatory Commission for clinical use under certificate  
number NR-525-D-101-S, and dated 2-11-1987.

All spent sources will be disposed of by Cintichem, Inc., the source  
manufacturer, as part of their source exchange program.

Should you have any questions regarding this application, please contact  
us at (808) 537-2211 Ext: 468.

Sincerely,

*Richard G. Smith*

Richard G. Smith  
Chief, Nuclear Medicine

RGS:ama

8801220634 870813  
REG5 LIC30  
53-16421-01 PDR

*Jul-1-87*  
*032 686*  
*4120*  
*7C*  
*And*  
*7/24/87*  
*7/24/87*  
*MAGN*

70596



LETTER REQUEST FO RADIOISOTOPE LICENSE AMENDMENT TO ADD THE  
CALICHEK FROM CALCORP, INC. AS ALTERNATIVE IN CHECKING  
LINEARITY OF DOSE CALIBRATOR.

DATE 18 JUNE 87

REF: RADIOISOTOPE LICENSE NUMBER 53-16421-01

Dear, US Nuclear Regulatory Commission:

Please accept this letter as our formal request to amend the license  
number listed above.

As an alternative to our present procedure, the dose calibrator can be  
checked for activity linearity with the use of a device called Calichek  
from Calcorp, Inc. The manufacturer's instructions for use as revised  
on March 2, 1982, will be followed. Test results will be recorded and  
retained for inspection. Corrective action as stated in our license  
application will be followed if unacceptable linearity is demonstrated.

Should you have any questions regarding this application, please contact  
us at (808) 537-2211 Ext: 468.

Sincerely,

Richard C. Smith  
Chief, Nuclear Medicine

RGS:ama

RECEIVED  
HRC

1981 JUN 26 A 10:11

REGION V